Thawing systems are utilized for defrosting biological samples in pharmaceutical companies, diagnostic centers, biotechnology, and biobanks. Thawing comes under the primary manufacturing processes in the biopharmaceutical industry. Thawing systems comprise of containers and thaw bags for process development. Thawing systems benefit the research and development process by minimizing the amount of sample required.
Demand for thawing system is largely driven by the biopharmaceutical industry. Biopharmaceutical companies that are involved in the production of drugs require thawing systems for transporting and storing pharmaceutical products & services. Factors such as short process cycles and sterile designs have led end-users to increasingly opt for thawing systems. Various bio-repositories across the globe are making high investments in expanding their storage capacities. In addition, thawed cells current find extensive use in the analysis and treatment of diseases such as cancer and diabetes. Growing number of road accidents, trauma cases, and emergencies have further driven the demand for biological samples, which in turn require thawing systems for storage and transport purposes.
However, small- & medium-sized companies find it difficult to invest in thawing systems on the back of their high cost. In addition, multiple thawing system are less optimal operationally for large batch size of samples. High cost of automation is further inhibiting expansion of the Thawing System Market. According to Transparency Market Research (TMR), the global thawing system market will register a CAGR of over 10% throughout the forecast period (2017-2026). Revenues from worldwide sales of thawing systems are estimated to reach approximately US$ 350 Mn by 2026-end.
Request to View Sample of Report –
Low cost of manual thawing systems is the primary reason why they are increasingly being preferred by healthcare settings. Manual thawing system is expected to be the dominant product in the market in 2017. However, advanced applications of automated thawing systems have spurred their demand across the biopharmaceutical companies as well as research institutes, owing to their high efficacy and effectiveness. Automated thawing systems are projected to outgrow manual thawing systems in terms of revenues by 2026-end.
Increasing incidences of blood related disorders such as rare blood disorders have driven the demand for blood for treatment and surgical purposes. In addition, growing number of accidents and trauma cases necessitate blood transfusions, along with demand for cryopreserved blood products. These factors have made blood to be the most lucrative sample type segment in the global thawing systems market. Semen will also remain a lucrative sample in the market, with sales projected to exhibit the highest CAGR through 2026.
Request to View Brochure of Report –
Key market participants identified by TMR’s report include BioCision, LLC, Cytotherm Lp, Barkey GmbH & Co. KG, Boekel Industries, Inc., Helmer, Inc., Cardinal Health, Inc., General Electric Company, and Sartorius Aktiengesellschaft.
This post was originally published on Market Reports